These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 32609812)

  • 1. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    van den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; de Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2021 Aug; 23(8):1415. PubMed ID: 32609812
    [No Abstract]   [Full Text] [Related]  

  • 2. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
    Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
    Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
    Hoogstrate Y; Vallentgoed W; Kros JM; de Heer I; de Wit M; Eoli M; Sepulveda JM; Walenkamp AME; Frenel JS; Franceschi E; Clement PM; Weller M; van Royen ME; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; Golfinopoulos V; van den Bent M; French PJ
    Neurooncol Adv; 2020; 2(1):vdz051. PubMed ID: 32642719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
    Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
    Gan HK; Reardon DA; Lassman AB; Merrell R; van den Bent M; Butowski N; Lwin Z; Wheeler H; Fichtel L; Scott AM; Gomez EJ; Fischer J; Mandich H; Xiong H; Lee HJ; Munasinghe WP; Roberts-Rapp LA; Ansell PJ; Holen KD; Kumthekar P
    Neuro Oncol; 2018 May; 20(6):838-847. PubMed ID: 29077941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
    Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ
    J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
    van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
    Jakacki RI; Cohen KJ; Buxton A; Krailo MD; Burger PC; Rosenblum MK; Brat DJ; Hamilton RL; Eckel SP; Zhou T; Lavey RS; Pollack IF
    Neuro Oncol; 2016 Oct; 18(10):1442-50. PubMed ID: 27006176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
    Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
    Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
    Rosenthal M; Clement PM; Campone M; Gil-Gil MJ; DeGroot J; Chinot O; Idbaih A; Gan H; Raizer J; Wen PY; Pineda E; Donnet V; Mills D; El-Hashimy M; Mason W
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32665311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
    Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H
    J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
    Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.